GlaxoSmithKline PLC ADR (GSK) - Net Assets
Based on the latest financial reports, GlaxoSmithKline PLC ADR (GSK) has net assets worth $15.99 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($61.01 Billion) and total liabilities ($45.02 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of GlaxoSmithKline PLC ADR to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.99 Billion |
| % of Total Assets | 26.22% |
| Annual Growth Rate | 6.92% |
| 5-Year Change | -44.67% |
| 10-Year Change | 222.28% |
| Growth Volatility | 119.62 |
GlaxoSmithKline PLC ADR - Net Assets Trend (1985–2025)
This chart illustrates how GlaxoSmithKline PLC ADR's net assets have evolved over time, based on quarterly financial data. Also explore GlaxoSmithKline PLC ADR total assets for the complete picture of this company's asset base.
Annual Net Assets for GlaxoSmithKline PLC ADR (1985–2025)
The table below shows the annual net assets of GlaxoSmithKline PLC ADR from 1985 to 2025. For live valuation and market cap data, see GlaxoSmithKline PLC ADR market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $15.99 Billion | +22.23% |
| 2024-12-31 | $13.09 Billion | -19.77% |
| 2023-12-31 | $16.31 Billion | +61.56% |
| 2022-12-31 | $10.10 Billion | -65.07% |
| 2021-12-31 | $28.91 Billion | +1.63% |
| 2020-12-31 | $28.44 Billion | +16.96% |
| 2019-12-31 | $24.32 Billion | +562.27% |
| 2018-12-31 | $3.67 Billion | +5.25% |
| 2017-12-31 | $3.49 Billion | -29.70% |
| 2016-12-31 | $4.96 Billion | -44.10% |
| 2015-12-31 | $8.88 Billion | +79.86% |
| 2014-12-31 | $4.94 Billion | -36.82% |
| 2013-12-31 | $7.81 Billion | +15.78% |
| 2012-12-31 | $6.75 Billion | -23.56% |
| 2011-12-31 | $8.83 Billion | -9.42% |
| 2010-12-31 | $9.74 Billion | -9.28% |
| 2009-12-31 | $10.74 Billion | +29.14% |
| 2008-12-31 | $8.32 Billion | -16.06% |
| 2007-12-31 | $9.91 Billion | +2.72% |
| 2006-12-31 | $9.65 Billion | +27.45% |
| 2005-12-31 | $7.57 Billion | +27.51% |
| 2004-12-31 | $5.94 Billion | -29.78% |
| 2003-12-31 | $8.45 Billion | +14.43% |
| 2002-12-31 | $7.39 Billion | -12.02% |
| 2001-12-31 | $8.40 Billion | -6.23% |
| 2000-12-31 | $8.96 Billion | +180.46% |
| 1999-12-31 | $3.19 Billion | +15.35% |
| 1998-12-31 | $2.77 Billion | +46.46% |
| 1997-12-31 | $1.89 Billion | +49.17% |
| 1996-12-31 | $1.27 Billion | +473.30% |
| 1995-12-31 | $221.00 Million | -61.54% |
| 1994-12-31 | $574.69 Million | -88.84% |
| 1993-12-31 | $5.15 Billion | +10.56% |
| 1992-12-31 | $4.66 Billion | +27.97% |
| 1991-12-31 | $3.64 Billion | +10.88% |
| 1990-12-31 | $3.28 Billion | +17.01% |
| 1989-12-31 | $2.81 Billion | +21.27% |
| 1988-12-31 | $2.31 Billion | +28.29% |
| 1987-12-31 | $1.80 Billion | +23.16% |
| 1986-12-31 | $1.46 Billion | +33.09% |
| 1985-12-31 | $1.10 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GlaxoSmithKline PLC ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1019105600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $10.19 Billion | 62.34% |
| Common Stock | $1.35 Billion | 8.24% |
| Other Components | $4.81 Billion | 29.43% |
| Total Equity | $16.35 Billion | 100.00% |
GlaxoSmithKline PLC ADR Competitors by Market Cap
The table below lists competitors of GlaxoSmithKline PLC ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sanofi
MX:SNYN
|
$111.20 Billion |
|
Parker-Hannifin Corporation
NYSE:PH
|
$111.35 Billion |
|
FAST RETAIL.CO.SP.HDR 1
F:FR7H
|
$111.69 Billion |
|
China Life Insurance Co Ltd A
SHG:601628
|
$111.74 Billion |
|
Intuit Inc
NASDAQ:INTU
|
$111.04 Billion |
|
Accenture plc
NYSE:ACN
|
$110.67 Billion |
|
FAST RETAIL. CO. ADR 1/10
F:FR70
|
$110.46 Billion |
|
Starbucks Corporation
NASDAQ:SBUX
|
$110.42 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GlaxoSmithKline PLC ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,671,000,000 to 16,348,214,000, a change of 2,677,214,000 (19.6%).
- Net income of 5,590,736,000 contributed positively to equity growth.
- Dividend payments of 2,507,811,057 reduced retained earnings.
- Share repurchases of 1,362,000,000 reduced equity.
- New share issuances of 15,000,000 increased equity.
- Other factors increased equity by 941,289,057.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $5.59 Billion | +34.2% |
| Dividends Paid | $2.51 Billion | -15.34% |
| Share Repurchases | $1.36 Billion | -8.33% |
| Share Issuances | $15.00 Million | +0.09% |
| Other Changes | $941.29 Million | +5.76% |
| Total Change | $- | 19.58% |
Book Value vs Market Value Analysis
This analysis compares GlaxoSmithKline PLC ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.00x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 60.43x to 7.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.92 | $55.63 | x |
| 1986-12-31 | $1.22 | $55.63 | x |
| 1987-12-31 | $1.51 | $55.63 | x |
| 1988-12-31 | $1.92 | $55.63 | x |
| 1989-12-31 | $1.14 | $55.63 | x |
| 1990-12-31 | $1.34 | $55.63 | x |
| 1991-12-31 | $1.48 | $55.63 | x |
| 1992-12-31 | $1.88 | $55.63 | x |
| 1993-12-31 | $2.07 | $55.63 | x |
| 1994-12-31 | $0.16 | $55.63 | x |
| 1995-12-31 | $0.03 | $55.63 | x |
| 1996-12-31 | $0.43 | $55.63 | x |
| 1997-12-31 | $0.64 | $55.63 | x |
| 1998-12-31 | $0.93 | $55.63 | x |
| 1999-12-31 | $1.08 | $55.63 | x |
| 2000-12-31 | $3.14 | $55.63 | x |
| 2001-12-31 | $3.08 | $55.63 | x |
| 2002-12-31 | $2.77 | $55.63 | x |
| 2003-12-31 | $3.33 | $55.63 | x |
| 2004-12-31 | $2.49 | $55.63 | x |
| 2005-12-31 | $3.19 | $55.63 | x |
| 2006-12-31 | $4.11 | $55.63 | x |
| 2007-12-31 | $4.31 | $55.63 | x |
| 2008-12-31 | $3.79 | $55.63 | x |
| 2009-12-31 | $4.90 | $55.63 | x |
| 2010-12-31 | $4.33 | $55.63 | x |
| 2011-12-31 | $3.94 | $55.63 | x |
| 2012-12-31 | $2.91 | $55.63 | x |
| 2013-12-31 | $3.56 | $55.63 | x |
| 2014-12-31 | $2.54 | $55.63 | x |
| 2015-12-31 | $4.54 | $55.63 | x |
| 2016-12-31 | $2.53 | $55.63 | x |
| 2017-12-31 | $1.77 | $55.63 | x |
| 2018-12-31 | $2.19 | $55.63 | x |
| 2019-12-31 | $7.53 | $55.63 | x |
| 2020-12-31 | $9.89 | $55.63 | x |
| 2021-12-31 | $12.58 | $55.63 | x |
| 2022-12-31 | $5.19 | $55.63 | x |
| 2023-12-31 | $8.28 | $55.63 | x |
| 2024-12-31 | $6.60 | $55.63 | x |
| 2025-12-31 | $7.94 | $55.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GlaxoSmithKline PLC ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 34.20%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.50%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 3.73x
- Recent ROE (34.20%) is below the historical average (95.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 36.70% | 27.99% | 0.79x | 1.65x | $291.00 Million |
| 1986 | 35.17% | 29.29% | 0.74x | 1.63x | $365.00 Million |
| 1987 | 32.57% | 28.22% | 0.72x | 1.61x | $402.60 Million |
| 1988 | 30.03% | 26.77% | 0.74x | 1.51x | $458.90 Million |
| 1989 | 29.54% | 25.39% | 0.71x | 1.64x | $533.80 Million |
| 1990 | 27.46% | 25.93% | 0.59x | 1.79x | $560.20 Million |
| 1991 | 28.92% | 25.22% | 0.72x | 1.59x | $675.80 Million |
| 1992 | 26.55% | 24.48% | 0.66x | 1.64x | $752.40 Million |
| 1993 | 25.85% | 22.97% | 0.72x | 1.57x | $796.40 Million |
| 1994 | 253.19% | 16.04% | 0.80x | 19.74x | $998.26 Million |
| 1995 | 1602.20% | 13.90% | 1.23x | 93.86x | $1.45 Billion |
| 1996 | 163.02% | 23.94% | 1.00x | 6.79x | $1.87 Billion |
| 1997 | 100.38% | 23.18% | 0.95x | 4.58x | $1.67 Billion |
| 1998 | 67.95% | 23.00% | 0.85x | 3.46x | $1.57 Billion |
| 1999 | 57.64% | 21.33% | 0.81x | 3.32x | $1.50 Billion |
| 2000 | 53.97% | 23.02% | 0.84x | 2.80x | $3.39 Billion |
| 2001 | 41.15% | 15.10% | 0.93x | 2.92x | $2.35 Billion |
| 2002 | 59.79% | 18.55% | 0.95x | 3.39x | $3.28 Billion |
| 2003 | 58.08% | 20.91% | 0.89x | 3.11x | $3.71 Billion |
| 2004 | 68.24% | 19.55% | 0.87x | 4.01x | $3.33 Billion |
| 2005 | 64.12% | 21.65% | 0.80x | 3.72x | $3.96 Billion |
| 2006 | 57.40% | 23.20% | 0.91x | 2.72x | $4.45 Billion |
| 2007 | 54.35% | 22.95% | 0.73x | 3.23x | $4.26 Billion |
| 2008 | 58.03% | 18.90% | 0.62x | 4.97x | $3.81 Billion |
| 2009 | 55.28% | 19.50% | 0.66x | 4.28x | $4.53 Billion |
| 2010 | 18.39% | 5.76% | 0.68x | 4.73x | $745.30 Million |
| 2011 | 65.50% | 19.21% | 0.67x | 5.11x | $4.46 Billion |
| 2012 | 77.44% | 17.02% | 0.64x | 7.14x | $3.92 Billion |
| 2013 | 77.69% | 20.51% | 0.63x | 6.01x | $4.74 Billion |
| 2014 | 55.83% | 11.98% | 0.57x | 8.24x | $2.26 Billion |
| 2015 | 94.86% | 35.20% | 0.45x | 6.02x | $7.53 Billion |
| 2016 | 18.38% | 3.27% | 0.47x | 11.90x | $415.70 Million |
| 2017 | 43.91% | 5.08% | 0.54x | 16.16x | $1.18 Billion |
| 2018 | 83.10% | 11.75% | 0.53x | 13.32x | $3.19 Billion |
| 2019 | 30.74% | 13.76% | 0.32x | 6.99x | $3.13 Billion |
| 2020 | 28.83% | 23.61% | 0.22x | 5.51x | $3.76 Billion |
| 2021 | 21.50% | 17.76% | 0.23x | 5.25x | $2.35 Billion |
| 2022 | 141.12% | 51.00% | 0.49x | 5.68x | $13.90 Billion |
| 2023 | 28.96% | 16.25% | 0.40x | 4.42x | $3.23 Billion |
| 2024 | 18.84% | 8.21% | 0.53x | 4.35x | $1.21 Billion |
| 2025 | 34.20% | 17.50% | 0.52x | 3.73x | $3.96 Billion |
Industry Comparison
This section compares GlaxoSmithKline PLC ADR's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $17,842,239,333
- Average return on equity (ROE) among peers: 28.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GlaxoSmithKline PLC ADR (GSK) | $15.99 Billion | 36.70% | 2.81x | $111.15 Billion |
| AbbVie Inc (ABBV) | $4.49 Billion | 91.90% | 5.50x | $365.30 Billion |
| Amgen Inc (AMGN) | $25.78 Billion | 20.01% | 1.68x | $177.77 Billion |
| Amarin Corporation PLC (AMRN) | $667.10 Million | 1.16% | 0.60x | $292.71 Million |
| AstraZeneca PLC (AZN) | $23.95 Billion | 26.05% | 1.24x | $286.40 Billion |
| Biogen Inc (BIIB) | $5.81 Billion | 13.49% | 0.46x | $27.45 Billion |
| Bristol-Myers Squibb Company (BMY) | $12.21 Billion | 42.98% | 1.42x | $118.52 Billion |
| Gilead Sciences Inc (GILD) | $1.87 Billion | 24.02% | 0.15x | $163.34 Billion |
| Johnson & Johnson (JNJ) | $70.42 Billion | 23.49% | 1.01x | $547.37 Billion |
| Eli Lilly and Company (LLY) | $15.39 Billion | 15.53% | 1.36x | $862.20 Billion |
About GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more